.
MergerLinks Header Logo

Announced

Completed

Maravai LifeSciences completed the acquisition of MyChem for $240m.

Financials

Edit Data
Transaction Value£178m
Consideration TypeCash, Contingent Deferred Consideration
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Majority

Domestic

Biotechnology

Acquisition

biotechnology company

Completed

United States

Single Bidder

Friendly

Private

nucleotides

Synopsis

Edit

Maravai LifeSciences, a global provider of life science reagents and services to researchers and biotech innovators, completed the acquisition of MyChem, a privately held provider of proprietary, ultra-pure nucleotides to customers in the diagnostics, pharma, genomics and research markets, for $240m. "MyChem’s chemically synthesized nucleotides are a natural fit and complementary product line for our Nucleic Acid Production business. We have worked with MyChem since 2018 and have the highest regard for the founders and the team they have built and believe there is a close alignment of company cultures. Similar to our past acquisitions, MyChem is founder-led with exceptional science in place where we can help scale the organization and accelerate growth," Carl Hull, Maravai CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US